Aura Biosciences(US:AURA)2026-03-30 11:05Financial Performance - The net loss for the full year 2025 was $106.2 million, compared to a net loss of $86.9 million in 2024[17]. - The total operating loss for the full year 2025 was $112.8 million, compared to $96.1 million in 2024[20]. - General and administrative expenses decreased to $22.5 million for the full year 2025, down from $22.8 million in 2024, driven by reduced professional fees[17]. - Research and development expenses for the full year 2025 were $90.3 million, an increase from $73.3 million in 2024, primarily due to ongoing clinical trial costs[17]. - As of December 31, 2025, the company had cash and cash equivalents and marketable securities totaling $144.2 million, sufficient to fund operations into Q1 2027[17]. Clinical Trials and Developments - The ongoing Phase 3 CoMpass trial is expected to complete enrollment by mid-2026, with topline data anticipated in the second half of 2027[2]. - Initial three-month clinical data from the Phase 1b/2 NMIBC trial is expected in mid-2026[2]. - The ongoing Phase 2 trial for bel-sar in metastases to the choroid is on track to report early data in 2026, addressing a high unmet medical need[10]. - The company achieved 12-month stability for a new formulation designed for non-ocular solid tumors, starting with urologic oncology[8]. - The company has received FDA Fast Track designation for bel-sar in the treatment of early choroidal melanoma and metastases to the choroid[5].